Available products

Download PDF Product list

Product Family Name Dosage Form Dosage Strength Development Status Dossier Readiness ATC Group 4B Zone Stability* Available Territory
ABACAVIR SULFATE + LAMIVUDINE Film-coated tablet 600 + 300 mg ready EU registered Antiinfectives for systemic use No Global
ABIRATERONE ACETATE Film-coated tablet 500 mg ready filed in EU Antineoplastic and immunomodulating agents Yes Global
AGOMELATINE  Film-coated tablet   25 mg  ready  registered  Antidepressant  Can be added  Global
ACETYLSALICYLIC ACID Tablet 100 mg, 500mg ready EU registered Nervous system No Germany
AMLODIPINE Tablet 2.5 mg, 5mg, 10mg ready EU registered Cardiovascular system Yes Global
AMLODIPINE BESILATE + CANDESARTAN CILEXETIL Tablet 5 mg + 8 mg; 10 mg + 16 mg ready EU registered Cardiovascular system No Europe
 AMLODIPINE BESILATE + CANDESARTAN CILEXETIL  Tablet  5 mg + 16 mg  ready  partially registered  Cardiovascular system  No Global
AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINE Tablet 5 mg + 1.25 mg + 4 mg, 10 mg + 1.25 mg + 4 mg, 5 mg + 2.5 mg + 8 mg , 10 mg + 2.5 mg + 8 mg ready filed in EU Cardiovascular system No Global
AMLODIPINE BESILATE + PERINDOPRIL ERBUMINE Film-coated tablet 5 mg + 4 mg, 10 mg + 4 mg, 5 mg + 8 mg, 10 mg + 8 mg ready EU registered Cardiovascular system No Global
AMLODIPINE BESILATE + VALSARTAN Film-coated 5 mg + 80 mg, 5 mg + 160 mg, 10 mg + 160 mg ready EU registered Cardiovascular system No Europe
APIXABAN Film-coated tablet 2.5 mg, 5 mg ongoing Q2 2022 Blood and blood forming organs No Europe
APREMILAST Film-coated tablet 10 mg, 20 mg, 30 mg ongoing Q4 2022 Dermatological drugs At risk Global
ATAZANAVIR SULFATE Capsule, hard 300 mg ready EU registered Antiinfectives for systemic use Yes Global
ATORVASTATIN CALCIUM Film-coated tablet 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg ready EU registered Cardiovascular system No Europe
BISOPROLOL FUMARATE Tablet 1.25 mg; 2.5 mg; 3.75 mg; 5 mg; 7.5 mg; 10 mg ready EU registered Cardiovascular system No Global
CLOPIDOGREL BISULPHATE Film-coated tablet 75 mg ongoing Q1 2023 Blood and blood forming organs can be added Global
DAPAGLIFLOZIN Film-coated tablet 5 mg, 10 mg ongoing Q3 2024 Alimentary tract and metabolisma can be added Global
DEFERASIROX Film-coated tablet 90 mg, 180mg, 360mg ready EU registered Various ATC structures No Global
DROSPIRENONE + ESTRADIO  Film-coated tablet   2 mg + 1 mg ready ready Hormone replacement therapy No Europe
DULOXETINE HYDROCHLORIDE Capsule, gastro-resistant, hard 30 mg, 60 mg ready EU registered Nervous system No Global
DULOXETINE HYDROCHLORIDE Capsule, gastro-resistant, hard 20 mg, 40 mg ready registered Urology No Europe
EDOXABAN Film-coated tablet 15 mg, 30 mg, 60 mg ongoing Q3 2023 Nervous system can be added Global
EMTRICITABINE + RILPIVIRINE +TENOFOVIR ALAFENAMIDE Film-coated tablet 200 mg + 25 mg + 25 mg 200 mg + 27.5 mg + 28 mg ongoing Q2 2024 Antivirotic can be added Global
EMTRICITABINE + TENOFOVIR ALAFENAMIDE Film-coated tablet 200 mg + 10 mg 200 mg + 25 mg  ongoing Q1 2024 Antivirotic can be added Global
EMPAGLIFLOZIN Film-coated tablet 10 mg, 25 mg ongoing Q1 2024 Alimentary tract and metabolisma can be added Global
ETORICOXIB Film-coated tablet 30 mg, 60 mg, 90 mg, 120 mg ready EU registered Blood and blood forming organs No Europe
FINGOLIMOD Capsule, hard 0,5 mg ready filed in EU Multiple Sclerosis No Europe
HYDROCHLOROTHIAZIDE + LOSARTAN POTASSIUM Film-coated tablet 12.5 + 50 mg; 12.5 + 100 mg; 25 + 100 mg ready registered Cardiovascular system No Global
HYDROCHLOROTHIAZIDE + TELMISARTAN Tablet 12.5 + 40 mg; 12.5 + 80 mg; 25 + 80 mg ready EU registered Cardiovascular system No Global
IBANDRONATE SODIUM MONOHYDRATE Film-coated tablet 150 mg ready EU registered Musculoskeletal system No Europe
IBUPROFEN Film-coated tablet 200 mg, 400 mg, 600 mg, 800 mg ready filed in EU Musculoskeletal system No Global
ILOPROST Nebuliser solution 10 µg / 1 ml  ready EU registered Blood and blood forming organs No Europe
ILOPROST Nebuliser solution 20 µg / 1 ml ready filed in EU Blood and blood forming organs Yes Global
ILOPROST Solution for injection 100 µg / 1 ml (0.5 ml)  ready filed in EU Blood and blood forming organs
glass vial Global
IVABRADINE HYDROCHLORIDE Film-coated tablet 5 mg; 7.5 mg ready EU registered Cardiovascular system No Global
LACOSAMIDE Film-coated tablet 50 mg, 100 mg, 150 mg, 200 mg ready EU registered Nervous system Yes Global
LEVETIRACETAM Film-coated tablet 250 mg, 500 mg, 750 mg, 1000 mg ready EU registered Nervous system No Europe
LINAGLIPTIN Film-coated tablet 5 mg ready filed in UE Alimentary tract and metabolisma No Europe
METAMIZOLE SODIUM Film-coated Tablet 500mg ongoing filed in EU Nervous system yes to be discussed
METAMIZOLE SODIUM Injection 500 mg/ml (2 ml) ongoing Q4 2021 Nervous system can be added to be discussed
METFORMIN HYDROCHLORIDE Film-coated tablet 500 mg, 850 mg, 1000mg ready filed in EU Alimentary tract and metabolisma Yes Global
NOREPINEPHRINE Injection 1 mg / 1 ml ongoing Q2 2022 various at risk Global
PARACETAMOL Tablet 500mg, 1000mg ongoing filed in EU Nervous system Yes Global
PERINDOPRIL ARGININE Film-coated tablet 2.5 mg, 5 mg, 10 mg ongoing filed in EU Cardiovascular system No Global
PRASUGREL HYDROCHLORIDE Film-coated tablet 5 mg, 10 mg ongoing EU registered Blood and blood forming organs Yes Global
RAMIPRIL Tablet 1.25 mg, 2.5 mg, 5 mg, 10 mg ongoing Q4 2022 Cardiovascular system can be added Global
RIVAROXABAN Film-coated tablet 2.5 mg; 10 mg, 15 mg, 20 mg ready EU registered Blood and blood forming organs (Venous thromboembolism) No Europe
RIVAROXABAN Capsule, hard 2.5 mg; 10 mg, 15 mg, 20 mg ready EU registered Blood and blood forming organs (Venous thromboembolism) No Europe
ROSUVASTATIN CALCIUM Film-coated tablet 5 mg; 10 mg, 20 mg, 40 mg ready EU registered Cardiovascular system No Global
SACUBITRIL + VALSARTAN Film-coated tablet 25 + 25 mg, 50 + 50 mg, 100 + 100 mg ongoing Q4 2022 Cardiovascular system No Europe
SERTRALINE Tablet 25 mg ready registered Nervous system No Global
SERTRALINE Tablet 50 mg, 100 mg
ongoing Q4 2021 Nervous system No Global
SITAGLIPTIN PHOSPHATE Film-coated tablet 25 mg, 50 mg, 100 mg ongoing Q4 2021 Alimentary tract and metabolisma can be added Global
SITAGLIPTIN PHOSPHATE + METFORMIN Film-coated tablet 50 + 500 mg, 50 + 850 mg ongoing Q2 2022 Alimentary tract and metabolisma can be added Global
SOLIFENACIN SUCCINATE Film-coated tablet 5 mg, 10 mg ready registered Genitourinary system and reproductive hormones no Europe
TAMSULOSIN HYDROCHLORIDE Modified-release capsule, hard 0.4 mg ready registered Genitourinary system and reproductive hormones No Global
TICAGRELOR Film-coated tablet 60 mg, 90 mg ready Q2 2021 Blood and blood forming organs Yes Global
TORASEMIDE Tablet 2.5, 5, 10, 20, 50, 100, 200 mg ongoing Q1 2022 Cardiovascular system Yes Global
VARDENAFIL HYDROCHLORIDE TRIHYDRATE Film-coated tablet 5 mg, 10 mg, 20 mg ready registered Genitourinary system and reproductive hormones No Europe
VILDAGLIPTIN Tablet 50 mg ready registered Alimentary tract and metabolisma No Europe
VORTIOXETINE Film-coated tablet 5 mg, 10 mg, 15 mg, 20 mg 
ongoing 
Q1 2024 
Nervous system 
No Europe

*4B Zone stability can be fulfilled upon request if not available at the moment

Dosage Form: Film-coated tablet
Dosage Strength: 600 + 300 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Antineoplastic and immunomodulating agents
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 500 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Antineoplastic and immunomodulating agents
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 100 mg, 500 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Nervous system
4B Zone Stability* No
4B Zone Stability* Global

Dosage Form: Film-coated tablet
Dosage Strength: 25 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Antidepressant
4B Zone Stability* Can be added
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 2,5mg, 5mg, 10mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 5 mg + 8 mg, 10 mg + 16 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* NO 
Available Territory Europe

Dosage Form: Tablet
Dosage Strength: 5 mg + 16 mg
Development Status: ready
Dossier Readiness: partially registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 5 mg + 1.25 mg + 4 mg, 10 mg + 1.25 mg + 4 mg, 5 mg + 2.5 mg + 8 mg, 10 mg + 2.5 mg + 8 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 5 mg + 4 mg, 10 mg + 4 mg, 5 mg + 8 mg, 10 mg + 8 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg + 80 mg, 5 mg + 160 mg, 10 mg + 160 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory

Europe

Dosage Form: Film-coated tablet
Dosage Strength: 2.5 mg, 5 mg
Development Status: ongoing
Dossier Readiness: Q2 2022
ATC Group: Blood and blood forming organs
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 10 mg, 20 mg, 30 mg
Development Status: ongoing
Dossier Readiness: Q4 2022
ATC Group: Dermatological drugs
4B Zone Stability* At risk
Available Territory Global

Dosage Form: Capsule, hard
Dosage Strength: 300 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Antiinfectives for systemic use
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Europe

Dosage Form: Tablet
Dosage Strength: 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 75 mg
Development Status: ongoing
Dossier Readiness: Q1 2023
ATC Group: Blood and blood forming organs
4B Zone Stability* Can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: Q3 2024
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* Can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 90 mg, 180mg and 360mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Various ATC structures
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 2 mg + 1 mg
Development Status: ready
Dossier Readiness: ready
ATC Group: Hormone replacement therapy
4B Zone Stability* No
Available Territory Europe

Dosage Form: Capsule, gastro-resistant, hard
Dosage Strength: 30mg, 60 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Nervous system
4B Zone Stability* No
Available Territory Global

Dosage Form: Capsule, gastro-resistant, hard
Dosage Strength: 20 mg, 40 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Urology
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 15 mg, 30 mg, 60 mg
Development Status: ongoing
Dossier Readiness: Q3 2023
ATC Group: Blood and blood forming organs
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 10 mg, 25 mg
Development Status: ongoing
Dossier Readiness: Q1 2024
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 200 mg + 25 mg + 25 mg, 200 mg + 27.5 mg + 28 mg
Development Status: ongoing
Dossier Readiness: Q2 2024
ATC Group: Antivirotic
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 200 mg + 10 mg, 200 mg + 25 mg
Development Status: ongoing
Dossier Readiness: Q1 2024
ATC Group: Antivirotic
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 30 mg, 60 mg, 90 mg, 120 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Musculoskeletal system
4B Zone Stability* No
Available Territory Europe

Dosage Form: Capsule, hard
Dosage Strength: 0.5 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Multiple Sclerosis
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 12.5 mg + 50 mg, 12.5 mg + 100 mg, 25 mg + 100 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 12.5 + 40 mg; 12.5 + 80 mg; 25 + 80 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 150 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Musculoskeletal system
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 200 mg, 400 mg, 600 mg, 800 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Musculoskeletal system
4B Zone Stability* No
Available Territory Global

Dosage Form: Nebuliser solution
Dosage Strength: 10 µg / 1 ml
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Blood and blood forming organs
4B Zone Stability* No
Available Territory Europe

Dosage Form: Nebuliser solution
Dosage Strength: 20 µg / 1 ml
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Blood and blood forming organs
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Solution for injection
Dosage Strength: 100 µg / 1 ml (0.5 ml)
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Blood and blood forming organs
4B Zone Stability* glass vial
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg; 7.5 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 50 mg, 100 mg, 150 mg, 200 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Nervous system
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 250 mg, 500 mg, 750 mg, 1000 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Nervous system
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* No
Available Territory Europe

Dosage Form: Tablet
Dosage Strength: 500mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Nervous system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated Tablet
Dosage Strength: 500 mg)
Development Status: ongoing
Dossier Readiness: filed in EU
ATC Group: Nervous system
4B Zone Stability* Yes
Available Territory To be discussed

Dosage Form: Injection
Dosage Strength: 500 mg/ml (2 ml)
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Nervous system
4B Zone Stability* can be added
Available Territory to be discussed

Dosage Form: Film-coated tablet
Dosage Strength: 500 mg, 850 mg, 1000mg
Development Status: ready
Dossier Readiness:  filed in EU
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Injection
Dosage Strength: 1 mg / 1ml
Development Status: ongoing
Dossier Readiness: Q2 2022
ATC Group: various
4B Zone Stability* at risk
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 500mg, 1000mg
Development Status: ongoing
Dossier Readiness: field in EU
ATC Group: Nervous system
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 2.5 mg, 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: filed in EU
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg
Development Status: read
Dossier Readiness: EU registered
ATC Group: Blood and blood forming organs
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 1.25 mg, 2.5 mg, 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: Q4 2022
ATC Group: Cardiovascular system
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 2.5 mg; 10 mg, 15 mg, 20 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Blood and blood forming organs (Venous thromboembolism)
4B Zone Stability* No
Available Territory Europe

Dosage Form: Capsule, hard
Dosage Strength: 2.5 mg; 10 mg, 15 mg, 20 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Blood and blood forming organs (Venous thromboembolism)
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg; 10 mg, 15mg, 20 mg, 30mg, 40 mg
Development Status: ready
Dossier Readiness: EU registered
ATC Group: Cardiovascular system
4B Zone Stability* Yes
Available Territory

Europe

Dosage Form: Film-coated tablet
Dosage Strength: 25 mg + 25 mg, 50 mg + 50 mg, 100 mg + 100 mg, 
Development Status: ongoing
Dossier Readiness: Q4 2022
ATC Group: Cardiovascular system
4B Zone Stability* No
Available Territory Europe

Dosage Form: Tablet
Dosage Strength: 25 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Nervous system
4B Zone Stability* No
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 50 mg, 100 mg
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Nervous system
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 25 mg, 50 mg, 100 mg
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 50 + 500 mg, 50 + 850 mg
Development Status: ongoing
Dossier Readiness: Q2 2022
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* can be added
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Genitourinary system and reproductive hormones
4B Zone Stability* no
Available Territory Europe

Dosage Form: Modified-release capsule, hard
Dosage Strength: 0.4 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Genitourinary system and reproductive hormones
4B Zone Stability* No
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 60 mg, 90 mg
Development Status: ready
Dossier Readiness: Q2 2021
ATC Group: Blood and blood forming organs
4B Zone Stability* yes
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg
Development Status: ongoing
Dossier Readiness: Q1 2022
ATC Group: Cardiovascular system
4B Zone Stability* Yes
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg, 20 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Genitourinary system and reproductive hormones
4B Zone Stability* No
Available Territory Europe

Dosage Form: Tablet
Dosage Strength: 50 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* No
Available Territory Europe

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg, 15 mg, 20 mg
Development Status: ongoing
Dossier Readiness: Q1 2024
ATC Group: Nervous system
4B Zone Stability* No
Available Territory Europe

Available MA

Product Family Name Dosage Form Dosage Strength Development Status Dossier Readiness
ABACAVIR + LAMIVUDINE Film-coated tablet 600 mg + 300 mg EU DPC Poland

Available MA

Dosage Form: Film-coated tablet
Dosage Strength: 600 mg + 300 mg
Development Status: EU DPC
Dossier Readiness: Poland

Dosage Form: Orodispersible tablet
Dosage Strength: 5 mg, 10 mg, 20 mg
Development Status: EU DPC
Dossier Readiness: Czech Republic

Available API

Download PDF API list

Product Name Status
ARTICAINE HYDROCHLORIDE Available
GLIBENCLAMIDE Available
PENTOXIFYLLINE Available
AGOMELATINE CITRIC ACID ASMF available
APIXABAN ASMF available
SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE ASMF available
TENOFOVIR ALAFENAMIDE ASMF available
VORTIOXETINE HYDROBROMIDE ASMF available
ENZALUTAMIDE ASMF available
ELVITEGRAVIR ASMF available
FENPIVERINIUM BROMIDE ASMF available
PITOFENONE HYDROCHLORIDE ASMF available
VALSARTAN SODIUM ASMF available
TAMSULOSIN HYDROCHLORIDE Late stage development
SACUBITRIL SODIUM Late stage development
RILMENIDINE DIHYDROGENPHOSPHATE Late stage development 
NAFTIDROFURYL HYDROGEN OXALATE Late stage development 
CHLORPROTHIXENE HYDROCHLORIDE Late stage development 
RAMIPRIL Late stage development
RIVAROXABAN Early stage development
CLOPIDOGREL HYDROGENSULPHATE Early stage development
IVACAFTOR Early stage development
TEZACAFTOR Early stage development

 

 

DISCLAIMER:

Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.